Device Companies Follow New Map To Atrial Fibrillation

Device therapies for atrial fibrillation (AF) have so far failed to result in compelling efficacy across all types of disease and patients. The rates of elimination of AF following a catheter ablation procedure range from 30% to 80% according to the type of patient and the definition of success. The question of why success rates aren’t yet sufficient after a great deal of investment is an area of active pursuit, and one that opens up the door for next-generation AF device companies seeking to improve upon the results achieved to date.

In the cardiovascular device arena, as in so many other medical device fields, success tends to come only after halting progress. In coronary artery disease, for example, an interventional revolution began when angioplasty catheters were introduced to clear blocked arteries in the heart without the need for bypass surgery. However, plaque dissection and elastic recoil caused the vessels to abruptly close again, necessitating the development of stents to prop them open. Physicians soon discovered that bare-metal stents were plagued by high rates of gradual vessel re-closure (restenosis) due to accelerated neoinitimal cell growth inside the stented area, and drug-eluting stents came along to deal with that problem. Today, coronary revascularization procedures produce excellent long-term vessel patency, although not every problem has been solved and the field continues to evolve and improve. Atrial fibrillation (AF) ablation is following a similar path. Earlier versions of radiofrequency (RF) ablation catheters overheated tissue, so the tips were irrigated with saline to achieve a more controlled burn. Irrigation solved one problem but created another – electrophysiologists (EPs) no longer could use temperature measurement at the tissue surface to confirm that they had created adequate ablation lesions during the procedure. So sensors were developed to measure the force with which the ablation probe contacts tissue to give physicians feedback about whether or not they’re creating a competent lesion.

In the case of AF, however, these incremental advancements have so far failed to result in compelling efficacy across all types of disease and patients. The rates of AF elimination...

More from Archive

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By 

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.